132 related articles for article (PubMed ID: 30761858)
1. Farnesoid X receptor in human malignancies: an overview.
Giordano C; Barone I; Bonofiglio D; Catalano S; Andò S
J Biol Regul Homeost Agents; 2018; 32(4 Suppl. 1):1-7. 4° JOINT MEETING OF PATHOLOGY AND LABORATORY MEDICINE SIPMET–SIPMEL - SECOND JOINT MEETING IN COLLABORATION WITH ASIP–AMP–UEMS–WASPALM - 4° SIPMEL NATIONAL CONGRESS - 34° SIPMET NATIONAL CONGRESS - 4° CONGRESS OF PATHOLOGY AND LABORATORY MEDICINE. PubMed ID: 30761858
[No Abstract] [Full Text] [Related]
2. Farnesoid X receptors and their role in the etiopathogenesis of systemic malignancies.
Kapoor S
Am J Gastroenterol; 2008 Nov; 103(11):2958. PubMed ID: 19032488
[No Abstract] [Full Text] [Related]
3. [Progress in the role of farnesoid X receptor in metabolic regulation and tumor cell proliferation].
Xie Y; Zhou XY; Hao HP; Wang GJ
Sheng Li Xue Bao; 2014 Apr; 66(2):252-8. PubMed ID: 24777417
[TBL] [Abstract][Full Text] [Related]
4. Bile acids, farnesoid X receptor, atherosclerosis and metabolic control.
Kuipers F; Stroeve JH; Caron S; Staels B
Curr Opin Lipidol; 2007 Jun; 18(3):289-97. PubMed ID: 17495603
[TBL] [Abstract][Full Text] [Related]
5. Farnesoid X receptor agonists for primary biliary cirrhosis.
Lindor KD
Curr Opin Gastroenterol; 2011 May; 27(3):285-8. PubMed ID: 21297469
[TBL] [Abstract][Full Text] [Related]
6. [Farnesoid X receptor regulates glucose and lipid metabolisms].
Jiang Q; Peng J; Liu SN; Shen ZF
Yao Xue Xue Bao; 2015 Mar; 50(3):245-51. PubMed ID: 26118101
[TBL] [Abstract][Full Text] [Related]
7. Intestinal farnesoid X receptor puts a fresh coat of wax on fatty liver.
Tuominen I; Beaven SW
Hepatology; 2015 Aug; 62(2):646-8. PubMed ID: 25998695
[No Abstract] [Full Text] [Related]
8. Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.
Merk D; Steinhilber D; Schubert-Zsilavecz M
Expert Opin Drug Discov; 2014 Jan; 9(1):27-37. PubMed ID: 24261510
[TBL] [Abstract][Full Text] [Related]
9. Nuclear receptors and coregulators in inflammation and cancer.
Lee JS; Kim KI; Baek SH
Cancer Lett; 2008 Aug; 267(2):189-96. PubMed ID: 18433989
[TBL] [Abstract][Full Text] [Related]
10. Pyrrole[2,3-d]azepino compounds as agonists of the farnesoid X receptor (FXR).
Mehlmann JF; Crawley ML; Lundquist JT; Unwalla RJ; Harnish DC; Evans MJ; Kim CY; Wrobel JE; Mahaney PE
Bioorg Med Chem Lett; 2009 Sep; 19(18):5289-92. PubMed ID: 19683924
[TBL] [Abstract][Full Text] [Related]
11. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands.
Carotti A; Marinozzi M; Custodi C; Cerra B; Pellicciari R; Gioiello A; Macchiarulo A
Curr Top Med Chem; 2014; 14(19):2129-42. PubMed ID: 25388537
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of farnesoid X receptor expression in thyroid neoplasia.
Giaginis C; Tsoukalas N; Alexandrou P; Tsourouflis G; Dana E; Delladetsima I; Patsouris E; Theocharis S
Future Oncol; 2017 Aug; 13(20):1785-1792. PubMed ID: 28762281
[TBL] [Abstract][Full Text] [Related]
13. Yin Yang 1 and farnesoid X receptor: a balancing act in non-alcoholic fatty liver disease?
Legry V; Schaap FG; Delire B; Horsmans Y; Leclercq IA
Gut; 2014 Jan; 63(1):1-2. PubMed ID: 23474422
[No Abstract] [Full Text] [Related]
14. Farnesoid X receptor: An important factor in blood glucose regulation.
Hou Y; Fan W; Yang W; Samdani AQ; Jackson AO; Qu S
Clin Chim Acta; 2019 Aug; 495():29-34. PubMed ID: 30910597
[TBL] [Abstract][Full Text] [Related]
15. Liver X receptor α and farnesoid X receptor are major transcriptional regulators of OATP1B1.
Meyer Zu Schwabedissen HE; Böttcher K; Chaudhry A; Kroemer HK; Schuetz EG; Kim RB
Hepatology; 2010 Nov; 52(5):1797-807. PubMed ID: 20827719
[TBL] [Abstract][Full Text] [Related]
16. Alteration of FXR phosphorylation and sumoylation in liver in the development of adult catch-up growth.
Hu X; Zhang Q; Zheng J; Kong W; Zhang HH; Zeng TS; Zhang JY; Min J; Wu C; Chen LL
Exp Biol Med (Maywood); 2017 Feb; 242(3):297-304. PubMed ID: 27190252
[TBL] [Abstract][Full Text] [Related]
17. Identification of functional farnesoid X receptors in brain neurons.
Huang C; Wang J; Hu W; Wang C; Lu X; Tong L; Wu F; Zhang W
FEBS Lett; 2016 Sep; 590(18):3233-42. PubMed ID: 27545319
[TBL] [Abstract][Full Text] [Related]
18. Tissue-specific actions of FXR in metabolism and cancer.
Gadaleta RM; Cariello M; Sabbà C; Moschetta A
Biochim Biophys Acta; 2015 Jan; 1851(1):30-9. PubMed ID: 25139561
[TBL] [Abstract][Full Text] [Related]
19. Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.
Peng Z; Chen J; Drachenberg CB; Raufman JP; Xie G
J Biol Chem; 2019 May; 294(21):8529-8542. PubMed ID: 30967475
[TBL] [Abstract][Full Text] [Related]
20. Enterobacteria-mediated deconjugation of taurocholic acid enhances ileal farnesoid X receptor signaling.
Kuribayashi H; Miyata M; Yamakawa H; Yoshinari K; Yamazoe Y
Eur J Pharmacol; 2012 Dec; 697(1-3):132-8. PubMed ID: 23051670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
